This website only uses technically necessary cookies. No tracking, no analytics.
Bio Protocol
BIO#469
$0.02211+0.29%
Bio Protocol (BIO) is a tradable crypto asset listed under the Bio Protocol name. It currently changes hands at $0.058897, carries a market capitalization of roughly $126.3 million, and sits at rank 253 by market cap. That puts BIO in the mid-sized tier of listed crypto assets — well outside the megacaps, but with enough scale to attract steady attention.
The headline figure in this Bio Protocol report is trading activity. Daily turnover comes in around $349.1 million, comfortably above the project's own market value. For active traders, that kind of liquidity makes BIO easier to follow when momentum shifts or short-term moves pick up speed. The flip side: price action driven by rapid rotation rather than slow accumulation, so judging an entry from market cap alone can be misleading.
Seen as a whole, BIO's profile right now is mostly a story of liquidity and valuation. You get a low nominal price, a nine-figure market cap, and unusually heavy reported daily turnover for an asset of this size. A practical caveat for any Bio Protocol analysis May readers run: heavy volume does not cancel out volatility — it can amplify it once sentiment turns. When weighing BIO against other assets, watch whether volume stays elevated, how its market-cap rank shifts over time, and whether the current price holds up during busier trading windows. Those signals matter for any realistic Bio Protocol forecast.
This content was created with the assistance of generative AI. Learn more
What is Bio Protocol? A quick explainer
Bio Protocol (BIO) is a crypto asset priced at $0.058897 with a market cap of about $126.3 million. Its 24-hour trading volume is high relative to its size, so newcomers should track volatility alongside price.
Security check
Smart contract risk scan — checks for honeypots, hidden taxes and more.
This coin carries 2 risk flags. Not suitable for beginners. If you invest anyway: only money you can afford to lose entirely. No DCA plans, no leverage, no FOMO buys after a pump.
AI analysis
Clear bullish / neutral / bearish signal based on market data, on-chain security and macro signals.
Analysis from September 4, 2026
This analysis is refreshed automatically in the background.
Rating
Neutral68% confident
Confidence
Summary
Bio Protocol's data profile right now is a study in contrasts: steady-but-modest protocol activity on one hand, concentration and security concerns on the other. Roughly $3.78 million is currently committed to the protocol, though that figure slipped 4.70% over the past seven days despite a 9.29% jump in the most recent 24 hours. Contract checks offer some reassurance — the code is open-source, transfers carry no transaction taxes, and the token isn't flagged as a honeypot — but the security score sits at a middling 55 out of 100. The Fear & Greed Index reads 65 (Greed), yet its slide from 73 to 65 over the week suggests market enthusiasm is cooling, which softens what would otherwise be a supportive sentiment signal. Risk concentration is also a factor: the ten largest addresses hold 59.62% of measured tokens. For anyone tracking BIO, uncertainty stays elevated since current price performance, on-chain flows, developer activity, and token-unlock timing simply aren't available yet.
📰 Current News & Events
No current news is available at this time, so there are no verified headlines or events to tie to BIO's recent market behavior. Regulatory news specific to Bio Protocol is also unavailable, meaning event-driven effects can't be assessed as part of this coin analysis.
📈 Price Movement Analysis
BIO's current price and its 24-hour, 7-day, and 30-day changes aren't available, so pinning down recent price direction isn't possible right now. The token's all-time high stands at $0.888995, set on January 3, 2025, but without a current price, we can't say how far BIO sits from that peak. On the protocol side, TVL (total value locked — the funds committed to the protocol) climbed 9.29% in a single day but fell 4.70% across the week, pointing to a short-lived rebound inside a softer weekly trend. Worth noting: TVL reflects capital committed to the protocol, not BIO's market price, so it can't tell us why the token itself moved.
Strengths
✅The smart-contract code is open-source, so it can be independently examined, and the token isn't flagged as a honeypot — a type of contract designed to trap users' funds.
✅Token transfers carry 0% entry and exit taxes, cutting down on friction created directly by the contract.
✅Bio Protocol holds around $3.78 million in TVL (capital committed to the protocol), split between roughly $2.09 million on Ethereum and $1.69 million on Base.
✅TVL rose 9.29% over the latest day, a recent rebound in committed capital despite the weaker weekly picture.
✅The security dataset counts 11,159 token-owning addresses, and BIO has a presence across several ecosystems, including Ethereum, Base, Solana, and BNB Chain.
Risks
⚠️The ten largest addresses control 59.62% of the measured token balance — that kind of concentration means moves by just a handful of big holders could swing the market disproportionately.
⚠️The contract's trust score is just 55 out of 100. BIO is also mintable, meaning new tokens can technically be created, though who controls that function remains unclear.
⚠️Only 64.61% of the maximum supply is currently circulating, and the token-unlock schedule isn't available — so any potential supply additions over the next 30 days can't be evaluated.
⚠️TVL dropped 4.70% over seven days despite the one-day rebound, suggesting protocol capital hasn't yet settled into a consistently positive trend.
⚠️On-chain flows and developer activity are both unavailable — significant gaps, since they'd reveal whether large holders are shifting tokens toward exchanges and whether the project is being actively maintained.
📊 Macro context
The Fear & Greed Index reads 65, in Greed territory, signaling that the broader crypto market still leans optimistic and risk-tolerant. That said, it dropped from 73 to 65 over the past week — an 8-point decline — so sentiment, while elevated, is clearly cooling; a reliable 90-day comparison isn't available. The Federal Funds Rate held steady at 3.63%, while annual inflation eased from 3.73% to 3.54%, a modest tailwind for risk-sensitive assets like crypto. The Dollar Index ticked up from 118.36 to 118.75, which could act as a headwind since a stronger dollar tends to dampen demand for crypto assets. Current regulatory developments affecting Bio Protocol are unavailable.
❓ Frequently Asked Questions
Is Bio Protocol (BIO) a good investment right now?
This coin analysis rates BIO a HOLD with 68% confidence. The picture is balanced but fragile: Greed-level market sentiment and steady protocol activity provide some support, while ownership concentration, a 55 security score, and significant information gaps keep confidence in check. This is investment research (MiFID II Del. Reg 2017/565 Art. 36), not an investment recommendation (MAR Art. 3(35)).
Why is BIO's price moving the way it is?
A clear explanation isn't possible right now, since BIO's current price changes and related news aren't available. TVL rose 9.29% in the last 24 hours but is still down 4.70% over seven days — a sign of uneven protocol activity rather than a defined trend, and a key point in any coin forecast for BIO.
What are the biggest risks and strengths in this BIO coin market analysis?
Strengths include open-source code, zero contract taxes, multichain activity, and roughly $3.78 million in TVL. The main risks are heavy concentration — the ten largest addresses hold 59.62% of tokens — plus minting capability, a 55 trust score, and missing data on development activity, on-chain flows, and token unlocks.
Bio Protocol's data picture leans heavily negative right now, largely because visible software development has stalled and several contract-related risks remain unresolved. The Fear & Greed Index sits at 71, in Greed territory, pointing to strong risk appetite across crypto — but that same enthusiasm raises the chance that sentiment has run ahead of fundamentals. Its seven-day trend actually slipped slightly, from 72 to 71. On the development side, tracked GitHub activity shows 0 commits, 0 merged pull requests, and no active contributors over the past four weeks. Add a security trust score of just 55, the contract's ability to mint additional tokens, and 59.57% concentration among the 10 largest wallets, and the uncertainty compounds further. Protocol deposits total roughly $4.02 million, with a 5.65% one-day recovery that stands in contrast to a 4.38% weekly decline. For anyone tracking BIO, missing price, on-chain flow, token-unlock, social-sentiment, and news data make this a harder coin analysis to verify — and that gap is exactly why confidence in a stronger conclusion stays limited.
Aug 20, 2026, 6:35 PM
NeutralNeutral · 78% confident
Bio Protocol's data tells two different stories at once. On one hand, deposits into the protocol are climbing fast. On the other, development activity has gone quiet and security indicators remain soft. The Fear & Greed Index — a widely-watched gauge of crypto market mood — sits at 62 (labeled 'Greed') after jumping 33 points from 29. That's a notable swing toward risk appetite, though such a fast move can also signal enthusiasm that hasn't been tested yet. Total value locked (TVL), the amount of capital deposited in the protocol, rose 14.44% in a single day and 20.56% over the past week, reaching roughly $4.18 million. That progress is tempered by a security trust score of just 55, heavy concentration with the ten largest holders controlling 59.49% of tokens, and zero recorded development activity over the past four weeks. Current price changes, project news, on-chain flows, social sentiment, and token-unlock details are all unavailable right now, which limits how far this coin analysis can go. For anyone tracking BIO, the takeaway is straightforward: sentiment and deposit growth look encouraging, but token-specific risks are real and thinly documented. This is investment research (MiFID II Del. Reg 2017/565 Art. 36), not investment advice.
